# Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C in the Russian Federation

> **NCT03868163** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 161 (actual)

## Conditions studied

- Chronic Hepatitis C (CHC)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03868163
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-28
- **Primary completion:** 2020-09-04
- **Final completion:** 2020-09-04
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2021-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03868163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03868163, "Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C in the Russian Federation". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT03868163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*